Group items tagged

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and recycling initiative. NHS Trusts and community pharmacies participating in the new scheme will have specialised recycling containers for inhalers installed to simplify public participation, Grundon said in a statement. Inhalers alone contribute to 4 per cent of NHS CO2 emissions, with around 73 million dispensed annually. By 2026, the health service aims to achieve a 50 per cent reduction in carbon emissions from waste management, a target that rises to 80 percent between 2028 and 2032, as outlined in the NHS Clinical Waste Strategy. "This scheme holds the potential to revolutionise the approach of NHS Trusts towards achieving heightened carbon savings and ultimately, net zero emissions," said Chris Edwards, Grundon's General Manager - Technical. "Each discarded pressurised Metered Dose Inhaler (pMDI) contains highly polluting hydrofluorocarbon (HFC) gases - a category of greenhouse gas known to be over a thousand times more detrimental than carbon dioxide in driving climate change." "This initiative securely captures these gases and repurposes them for application in the refrigeration sector. By also recycling the plastic and aluminium components of the device, we are making a noteworthy contribution to the circular economy," he added. Once collected, these will undergo processing at Grundon's specialist recycling facility in Ewelme, Oxfordshire, which is capable of handling more than 200,000 inhalers a day. The company aims to recycle 80 per cent of all prescribed inhalers by 2025, the statement added.

Global healthcare company Mundipharma and Vectura, an inhalation contract development and manufacturing organization, have entered into a collaboration agreement aimed at reformulating an asthma inhaler as part of their commitment to reducing the product's carbon footprint. The companies will be working together on incorporating an environmentally friendly propellant into the formulation of flutiform, a pressurised metered-dose inhaler (pMDI) used for asthma treatment, to achieve a near-zero-emissions product. Currently, the product uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant. The European Union's regulation on these types of greenhouse gases targets a two-thirds reduction in their usage and subsequent emissions by 2030. In a joint statement, companies revealed that work is already in progress to find an alternative to the HFA-227 gas. Yuri Martina, Chief Development and Medical Officer at Mundipharma, said: "This is the first step in our long-term plan to develop a near-zero-emissions asthma inhaler.

To combat the effects of climate change, the Integrated Care System (ICS) in South East London (SEL) has initiated a pioneering inhaler recycling project. Supported by NHS England and spanning 20 community pharmacies across the region, the project marks the first nationally-funded pilot of its kind in England, targeting the reduction of greenhouse gas emissions from improperly disposed inhalers. The project, which commenced at King's College Hospital in February 2024, focuses on the recycling of pressurised metered-dose inhalers. These inhalers, due to their propellant content, contribute significantly to environmental harm, emitting gases equivalent to driving 71.8 miles in a standard petrol car.

If you have asthma, it's important to know when you should see a doctor about an asthma flare-up. A flare-up is a sudden increase in your symptoms, which can include coughing, wheezing, chest tightness, and shortness of breath. Flare-ups can be mild or severe, and they can occur at any time. If you're not sure whether you're having a flare-up, here are six obvious signs that it might be time to see a doctor. 1. YOU'RE USING YOUR INHALER MORE THAN USUAL If you have asthma, you likely have a rescue inhaler that you use when you're having symptoms. This inhaler contains a medication that can quickly relieve your symptoms. If you find that you're using your rescue inhaler more often than usual, it could be a sign that your asthma is getting worse and you need to see a doctor. By seeking a doctor near me online, you can find a reputable physician who will accurately diagnose and treat your asthma. Always look for a second opinion, as one doctor's opinion might differ from others. For example, some doctors might recommend that you use a daily inhaler, while others might only recommend using it when you're having symptoms.

Several pharmacies have joined the inhaler recycling scheme in Wolverhampton, West Midlands, to support NHS England's Greener NHS programme, which aims to achieve net zero emissions by 2040. It is part of a collaborative working initiative between the Royal Wolverhampton NHS Trust and AstraZeneca UK Ltd, supported by the Black Country Integrated Care Board and Wolverhampton City Local Pharmaceutical Committee. Under this scheme, old and used inhalers are recycled and transformed into new products, such as coat hangers and waste bins. Simon Evans, group chief strategy officer for The Royal Wolverhampton NHS Trust, emphasised the importance of prioritising the reduction of carbon footprint while maintaining high-quality care, to protect the planet for future generations. "The Trust has already made significant achievements in several areas including the physical estate, clinical services, waste recycling, catering and medicines - with this inhaler recycling scheme from pharmacy being the latest string to our bow," he said.

Olbas has announced the launch of its new TV ad campaign which will debut across the country this October. The TV campaign, which will be supported by a £1.5 million pound media investment, has been directed by commercial film director, Anthony Farquhar-Smith. The latest Olbas advertising creative will feature a new animated character, Lauren who is suffering with congestion caused by a cold. Lauren will be seen at home as the house begins to fill with balloons causing Lauren to feel uncomfortable and restricted, mimicking the 'bunged up' feeling of a heavy head cold. Olbas then saves the day as we see Lauren reach for a bottle of Olbas Oil to ease the symptoms of congestion, and as a result, the balloons deflate and the house returns to normal. Along with the large media investment, the campaign will also benefit from a strong PR programme to ensure the brand and retail sales are well supported throughout the peak cold and flu season. Owned by family-run health business, Lanes Health, Olbas Oil continues to be manufactured at their Gloucester based factory. Olbas uses only natural essential oils to provide a gentle but effective formulation to ease congestion and enhance breathing passages. The product offer includes Olbas Oil, Olbas For Children, Olbas Inhaler, Olbas Nasal Spray, Olbas Menthol Pastilles and Olbas Bath.

Buy Best Quality Facial Steamers online at Tradzhub | India. We have a wide range of Facial Steamers Inhaler & Facial Sauna 3 In 1 Vaporizer online at Tradzhub | India at Tradzhub. Shop now and get up to 50% off...

The Royal Pharmaceutical Society and Scottish Academy of Medical Royal Colleges co-hosted the NHS Education for Scotland annual virtual conference to discuss the environmental impact of prescribing. One of the conclusions drawn from the conference on Thursday (April 28) stressed on environmentally sustainable prescribing should be embedded in undergraduate and postgraduate health care education. Delegates at the session said they or their teams needed more education. They also needed more information and resources when prescribing to be able to consider environmental issues. Sharon Pfleger, Consultant in Pharmaceutical Public Health at NHS Highland, told the session: "There's a lot of work to be done to reduce carbon emissions. The NHS has identified the use of metered-dose inhalers as its second biggest cause of carbon emissions as the propellant gases have significant global warming potential.

In a mutual agreement with the STADA board, Roger Scarlett-Smith has stepped down from his role as head of UK. The company has assigned the responsibility of UK operation to Rudolf Bär with current responsibilities as cluster head for Mid-Sized European Markets. Scarlett-Smith joined STADA in October 2018 to lead the UK operation upon the retirement of Dieno George. Prior to this, he had enjoyed an illustrious career in the Consumer Healthcare sector, largely with GlaxoSmithKline, for which he held positions including as President North America, President EMEA and Head of Global Categories. Under his leadership, the STADA UK business has grown sales by 50 per cent and profitability has more than doubled. He has reshaped the business to improve efficiency. There has been a marked acceleration of product innovation including key line extensions to the Zoflora disinfectant range as well as the introduction of a salmeterol and fluticasone inhaler in the Rx respiratory sector. Meanwhile, T+R has developed a fine reputation regionally, being voted number 1 regional company last year and winning many national industry awards.

The Pharmaceutical Services Negotiating Committee (PSNC) has reminded community pharmacy contractors to start working on the quality criteria if they intend to meet the Respiratory domain of the Pharmacy Quality Scheme (PQS) 2022/23. For respiratory domain, community pharmacy contractors  must start working towards inhaler waste management; use of a spacer in patients aged 5-15 years; and personalised asthma action plans, from today (10 October). Resources are also available to support contractors with meeting the above criteria on the PQS hub page. PSNC also informed that contractors are also now able to make a claim for an Aspiration payment for the PQS 2022/23 on the NHS Business Services Authority (NHSBSA)  Manage Your Service (MYS) portal. "The Aspiration payment is optional; if contractors do not want to claim it, it will not impact on the contractor's ability to claim a PQS payment during the declaration period. There is also no requirement to have claimed for a previous PQS to claim an Aspiration payment for PQS 2022/23.

Authorities in Northern Ireland have seized more than 242,000 unlicensed prescription tablets purchased online and destined for addresses throughout NI. The medicines seized include Diazepam, used for anti-anxiety treatment, Pregabalin, used for epilepsy and anxiety, steroids and Zopiclone. Other prescription medicines recovered included Tamoxifen, often used in the treatment of breast cancer and Salbutamol inhalers, frequently used in the treatment of asthma. "Co-operation between law enforcement agencies and government departments has led to the seizure of over 242,000 illegal and unlicensed tablets purchased online and destined for addresses throughout Northern Ireland," justice minister Naomi Long was reported as saying. The minister, together with health minister Robin Swann and assistant chief constable Mark McEwan PSNI were highlighting Northern Ireland's input to the global, Interpol co-ordinated Operation Pangea XV, which saw multiple packages of tablets intercepted and seized, with a street value of almost £250,000. She praised the concerted efforts made by PSNI, Border Force and officials from the Department of Health Medicines Regulatory Group during a specific week of action in June.

Have you ever wondered about the health benefits of ginseng? It's been used for thousands of years by people in Asia and Eastern Europe, but did you know it's good for more than just boosting energy? The ginseng plant deals with 11 combinations of short, slowly growing plants with fleshy roots. It can revive and improve well-being. This article will explore how this herbal plant can benefit your body. 11 Health Benefits of the Ginseng Plant There are two types of ginseng plants mainly: Asian or Korean ginseng (Panax ginseng) American ginseng (Panax quinquefolius). Studies have discovered that the distinct types have various uses. American ginseng is believed to be less stimulating in traditional Chinese medicine than the Asian one. There are several other herbs known as ginseng, like eleuthero or Siberian ginseng, but they don't have the valuable content of ginsenosides. Ginseng has traditionally been used for several medical illnesses. However, its benefits for most of them have yet to be thoughtfully researched. These include: 1/11_It may help your lungs work better. ginseng plant lowers lungs infections.Ginseng may also help your lungs, according to a published study in the Journal of Ethnopharmacology. Researchers found that one of the active ingredients in ginseng, ginsenoside Rg1 has an anti-inflammatory effect on the lungs and can even protect against asthma and bronchitis. They found that rats with asthma had less inflammation after being given doses of ginseng for two weeks compared to rats not given any. They also observed that rats with pneumonia had fewer symptoms when they were treated with inhaled doses of ginsenoside Rg1 or orally administered doses of Korean red ginseng extract (KRGE). 2/11_It may lower blood sugar levels. ginseng plant lower blood sugar levels. It's not just your imagination-ginseng can help lower blood sugar levels in people with diabetes. It also has been proven to reduce the amount of cholesterol in your body. It

The Department of Health and Social Care (DHSC) has issued a medicine supply notification for Sulfasalazine 250mg in 5ml oral suspension sugar free; Pilocarpine hydrochloride 4% eye drops; Fluticasone 50microgram / Salmeterol 25microgam (Combisal) pressurised metered dose inhaler (pMDI); and Dalteparin (Fragmin) 10,000units/1mL solution for injection ampoule on Wednesday (21 December). "Sulfasalazine 250mg/5ml oral suspension sugar free is out of stock from w/c 19th December until early June 2023. Sulfasalazine 500mg non-enteric coated tablets remain available "IPS Pharma, Nova Labs, and Rokshaw have currently confirmed they can manufacturer sulfasalazine 250mg/5ml oral suspension," said DHSC. Pilocarpine 4% eye drops are out of stock until w/c 26th December 2022. Alternative strengths of pilocarpine (1% and 2%) eye drops remain available and will be able to support increased demand. Specials of pilocarpine 4% preservative free eye drops are available if the licensed alternatives are not suitable. For off-label use of the 4% drops in the treatment of xerostomia (dry mouth) in palliative care, pilocarpine 5mg tablets are available and are licensed for this indication.

Two Indian pharmaceutical companies, Cipla and Glenmark, are pulling back certain products from the American market due to manufacturing concerns, according to the US Food and Drug Administration (USFDA). A New Jersey-based subsidiary of Cipla is recalling 59,244 packs of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution due to "short fill", news agency PTI reported, quoting the latest Enforcement Report issued by the US health regulator. Produced at the company's Indore SEZ plant, this medication is used to manage symptoms associated with lung diseases, such as asthma, chronic bronchitis and emphysema. Cipla USA decided to recall the affected lot following complaints of less fill volume in respule and few drops of liquid observed in the intact pouch, the USFDA said, adding that the drug maker initiated the Class II recall in the US market on March 26 this year.

More than a third of pharmacists who participated in a survey said they have seen an increase in patients declining prescriptions due to the cost in the last 12 months. The survey was jointly conducted by the Pharmacists' Defence Association (PDA) and the Royal Pharmaceutical Society (RPS), extending their support for the Prescription Charges Coalition (PCC). Responding to the survey, 90 per cent of pharmacists admitted seeing cases where patients decline all the medicines on a prescription due to cost. Nearly all respondents said they have seen cases where patients declined some of their prescribed medicines and more than a quarter of them have experienced such situation often. They have warned of the impact of prescription charges as patients are denying vital medicines, including those for blood pressure and mental health, inhalers, antibiotics, pain relief, and statins, which can have potential consequences for the individual's health.

Britain's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) on Monday announced that fluoroquinolone antibiotics must only be administered when no other antibiotics are appropriate for use. It elaborated that fluoroquinolones given systemically (by mouth, injection, or inhalation) should only be prescribed "when other recommended antibiotics have failed, will not work due to resistance, or are unsafe to use in an individual patient." Previous regulations on fluoroquinolones stated that this class of antibiotics should not be prescribed for mild to moderate or self-limiting infections, or non-bacterial conditions. Further restrictions have been introduced after receiving reports from patients who have experienced long-lasting or disabling reactions following use of fluoroquinolones, the MHRA revealed. Dr Alison Cave, MHRA Chief Safety Officer, said: "Patient safety is our top priority. We have listened to the experience of patients regarding long-lasting and potentially irreversible adverse reactions following use of fluoroquinolone antibiotics, in some cases prescribed for mild-to-moderate infections.

The #AskAboutAsthma annual campaign, led by NHS England - London's Babies, Children and Young People programme, is returning for its eighth year with a focus on promoting simple changes that can make a big difference to people living with asthma. Scheduled to take place from 9-15 September, this year' campaign aims to address broader factors such as vaping, air quality, housing conditions, and mould to ensure every child and young person in London with asthma receives the support and tools necessary to manage their condition effectively. Pharmacists are encouraged to support the 2024 #AskAboutAsthma campaign, themed "helping children and young people with asthma to live their best lives." They can contribute to the campaign in various ways, including: Offering inhaler technique checks to all children and young people with asthma. Identifying children and young people who are not regularly collecting their preventer medication and communicating this to their GP practice. Identifying children and young people who are collecting large amounts of reliever medication and communicating this to their GP practice.

Asthma makes breathing difficult for more than 300 million people worldwide according to the WHO. Treat your bronchial asthma/ breathlessness/ wheezing/ respiratory allergy with Homeopathy at Dr. Batra's

British drug discovery company C4X Discovery said AstraZeneca had signed a licence worth up $402 million to develop an oral therapy for the treatment of inflammatory and respiratory diseases using its NRF2 Activator programme. The Manchester-based company said on Monday (November 28) it would receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront. In addition, C4XD said it would receive a further potential $385.8 million in clinical development and commercial milestones and tiered mid-single digit royalties upon commercialisation of any treatment.